Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)
ID: 340192Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Public and State Controlled Institutions of Higher Education

Funding Category

Income Security and Social Services

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/340192

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-167.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity through the Clinical and Translational Science Award (CTSA) Program for the Collaborative and Innovative Acceleration Award (UG3/UH3), aimed at enhancing the translational research process. This initiative seeks innovative applications that foster collaboration among CTSA hubs and other stakeholders to address inefficiencies in translating research into clinical and public health interventions, particularly for underserved populations. The funding mechanism involves a two-phase cooperative agreement, with a focus on measurable milestones and sustainability plans to ensure impactful dissemination of successful interventions. Interested applicants, including public and state-controlled institutions of higher education, must submit their proposals by October 17, 2024, and can find additional information at the NIH grants website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-22-167.html
    The Clinical and Translational Science Award (CTSA) Program offers funding through the Collaborative and Innovative Acceleration Award (UG3/UH3) to support collaborative projects aimed at enhancing the translational research process. The National Center for Advancing Translational Sciences (NCATS), in concert with various participating NIH Institutes and the FDA, seeks innovative applications to tackle inefficiencies in translating research into clinical and public health interventions. Key emphases include fostering partnerships among CTSA hubs and other stakeholders to develop and demonstrate solutions that can accelerate translational science across diverse health challenges, particularly for underserved populations. The funding mechanism involves a two-phase cooperative agreement, optimizing project development in the UG3 phase and implementation in the UH3 phase. Each project must outline measurable milestones and sustainability plans, ensuring impactful dissemination of successful interventions. Eligible applicants include active CTSA hubs and their partners, encouraging interdisciplinary collaboration and innovative methodologies. The CTSA goals highlight a commitment to effectively bridging gaps within the translational science landscape while prioritizing minority health, regulatory science, and the application of emerging technologies in health research. This funding opportunity emphasizes the necessity of enhancing the productivity of clinical research and making interventions available to the public more rapidly and equitably.
    Similar Opportunities
    Clinical and Translational Science Award (UM1 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the Clinical and Translational Science Award (CTSA) Program, aimed at enhancing clinical and translational research through collaborative partnerships. This initiative invites applications for hubs that will focus on improving the efficiency of clinical translation, addressing health disparities, and fostering innovative research methodologies, with a particular emphasis on community engagement and workforce development. Successful applicants, which may include higher education institutions and nonprofit organizations, are expected to outline strategic management and demonstrate strong leadership, with projects capped at seven years and a submission deadline of September 28, 2027. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the funding opportunity page at https://grants.nih.gov/grants/guide/pa-files/PAR-24-272.html.
    Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards (RC2 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards." This initiative aims to support the development and demonstration of innovative resources and capabilities within Clinical and Translational Science Awards (CTSA) Program hubs, specifically targeting critical gaps and roadblocks in clinical research. Successful applicants, who must be active UM1 CTSA award recipients, will propose projects lasting up to five years with an annual budget cap of $500,000, emphasizing collaboration and innovation in health research. Interested parties should note that the application deadline is September 14, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards (RC2 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Limited Competition Funding Opportunity titled "High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards." This initiative aims to support the development of unique capabilities and resources to address critical gaps in clinical and translational science within awarded UM1 Clinical and Translational Science Awards (CTSA) Program Hubs. The funding opportunity, numbered PAR-25-156, allows for project budgets of up to $500,000 per year over a project period of up to five years, with applications involving clinical trials being optional. Interested applicants, primarily from public and state-controlled institutions of higher education, must submit detailed integration plans, milestones, and sustainability evaluations by the closing date of September 28, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Re-issue PAR-22-167 - Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to re-issue the Notice of Funding Opportunity Announcement (PAR-22-167) for the Clinical and Translational Science Award (CTSA) Program, specifically the Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional). This funding opportunity aims to foster meaningful collaborations and innovative projects in clinical and translational science, with no cost-sharing or matching requirements for eligible applicants, which include for-profit organizations. The estimated total program funding is $5 million, with an award ceiling of $650,000, and the NOFO is expected to be published in Fall 2024, with applications due in Winter 2025. Interested parties should prepare for the anticipated timeline, as the estimated project start date is December 1, 2025, and further details can be found on the CCIA webpage.
    Notice of Intent to Publish a Notice of Funding Opportunity for the Re-Issue of PAR-21-293 - Clinical and Translational Science Award (UM1 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to reissue a Notice of Funding Opportunity (NOFO) for the Clinical and Translational Science Award (CTSA) Program, aimed at establishing hubs that will contribute to a national consortium focused on accelerating the delivery of treatments to patients through advancements in clinical and translational science. This initiative is designed to foster meaningful collaborations and responsive projects among eligible applicants, which include various organizations and institutions. The anticipated NOFO is expected to be published in Summer 2024, with applications due by January 2025, and the estimated award date is set for December 16, 2025. Interested parties should prepare for the upcoming application process as no cost-sharing or matching is required for this cooperative agreement funding opportunity.
    Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award (CTSA) Program (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Center for Advancing Translational Sciences (NCATS), has announced a funding opportunity for the Limited Competition Small Grant Program (R03), aimed at supporting Clinical and Translational Science Award (CTSA) Program KL2/K12 scholars and diversity supplement recipients. This program is designed to facilitate the transition of these scholars to independent research careers by funding small, self-contained research projects that can be conducted quickly and with limited resources, ultimately addressing inefficiencies in translational science. Grants of up to $50,000 per year are available for projects lasting up to two years, with a submission deadline of January 17, 2025, and an anticipated award cycle beginning in February 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award (CTSA) Program (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award (CTSA) Program, designated as R03 Clinical Trial Optional. This funding opportunity aims to support KL2/K12 scholars and recipients of diversity and re-entry supplements in their transition to independent research roles by funding small, innovative, self-contained projects in translational science, with a maximum budget of $50,000 per year over a two-year period. The initiative is designed to enhance the capabilities of emerging researchers in addressing inefficiencies in translating research into clinical applications, engaging underrepresented populations, and improving data accessibility through innovative technologies. Applications will be accepted starting January 19, 2024, with multiple deadlines leading up to October 20, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional)" to support collaborative translational research projects aimed at bridging basic biological discoveries with clinical applications to enhance health outcomes. This program encourages partnerships between NIH intramural and extramural investigators, requiring that applications include at least one intramural scientist as a co-Principal Investigator and that a significant portion of the research is conducted at the NIH Clinical Center. The maximum funding amount is $500,000 in direct costs annually for up to four years, with applications due between January 5, 2026, and March 6, 2027. Interested applicants can reach out to David J. Eckstein at ClinicalCtrPartner@mail.nih.gov for further information.
    Opportunities for Collaborative Research at the NIH Clinical Center
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Opportunities for Collaborative Research at the NIH Clinical Center," aimed at supporting collaborative translational research projects that enhance the application of basic biological discoveries to clinical settings. This program encourages partnerships between NIH intramural investigators and extramural researchers to accelerate patient-centric translational research, focusing on understanding disease processes and developing new therapeutic interventions, diagnostics, or prevention strategies. Interested small businesses can apply for this cooperative agreement, with no cost-sharing requirement, and should note that the estimated synopsis post date is September 1, 2025, with a closing date of December 12, 2025. For further inquiries, applicants can contact Dr. David J. Eckstein at 301-496-4121 or via email at ClinicalCtrPartner@mail.nih.gov.
    Limited Competition: Mentored Research Career Development Program Award in Clinical and Translational Science Awards (CTSA) Program (K12 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a limited competition grant opportunity for the Mentored Research Career Development Program Award under the Clinical and Translational Science Awards (CTSA) Program. This initiative aims to develop innovative career advancement programs for later-stage postdoctoral fellows and junior faculty who are committed to independent clinical and translational science research careers, facilitating their transition into leadership roles through structured mentorship and research experiences. The program is designed to enhance the clinical and translational science workforce, addressing national biomedical research needs, and encourages diversity among scholars. Eligible institutions may submit a single K12 application alongside a UM1 application, with a funding period of up to five years. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov, with the application deadline set for September 28, 2027.